Abstract
Most drugs initiate their effects by binding to a drug target. The kinetics of binding have the potential to influence the utility of a drug. Physiology uses the magnitude of kinetic barriers to differentiate between reversible and irreversible states, leading to differentiated phenotypes. Under the appropriate circumstances the therapeutic index of some drugs is influenced by the kinetics and reversibility of a system. The ability for differentiated binding kinetics to define irreversible or reversible states and the impact of these differentiated states on a clinical outcome is proposed here to contribute to the magnitude of gastrointestinal toxicity observed with nonsteroidal anti-inflammatory agents (NSAIDs). This example and others highlight the potential for differentiated binding kinetics to provide clinical differentiation.
Keywords: Kinetics, Pharmacology, Cyclooxygenase, NSAID, GI toxicity, Irreversible
Letters in Drug Design & Discovery
Title: Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice
Volume: 3 Issue: 8
Author(s): David C. Swinney
Affiliation:
Keywords: Kinetics, Pharmacology, Cyclooxygenase, NSAID, GI toxicity, Irreversible
Abstract: Most drugs initiate their effects by binding to a drug target. The kinetics of binding have the potential to influence the utility of a drug. Physiology uses the magnitude of kinetic barriers to differentiate between reversible and irreversible states, leading to differentiated phenotypes. Under the appropriate circumstances the therapeutic index of some drugs is influenced by the kinetics and reversibility of a system. The ability for differentiated binding kinetics to define irreversible or reversible states and the impact of these differentiated states on a clinical outcome is proposed here to contribute to the magnitude of gastrointestinal toxicity observed with nonsteroidal anti-inflammatory agents (NSAIDs). This example and others highlight the potential for differentiated binding kinetics to provide clinical differentiation.
Export Options
About this article
Cite this article as:
Swinney C. David, Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice, Letters in Drug Design & Discovery 2006; 3 (8) . https://dx.doi.org/10.2174/157018006778194754
DOI https://dx.doi.org/10.2174/157018006778194754 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Osmolytes in Regulating Immune System
Current Pharmaceutical Design Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews Rosuvastatin Induced Rhabdomyolysis in a Low Risk Patient: A Case Report and Review of the Literature
Current Clinical Pharmacology Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Advances in Drug Therapy for Systemic Lupus Erythematosus
Current Medicinal Chemistry Recent Advancements in the Therapeutics of Food Allergy
Recent Patents on Food, Nutrition & Agriculture GRAPHICAL ABSTRACTS
Letters in Drug Design & Discovery (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Aspirin: A Potential Therapeutic Approach in Pancreatic Cancer
Current Medicinal Chemistry The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital
Current Clinical Pharmacology Computational Modeling of Dielectrophoretic Microfluidic Channel for Simultaneous Separation of Red Blood Cells and Platelets
Current Signal Transduction Therapy Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia
Current Vascular Pharmacology The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Microsomal Prostaglandin E2 Synthase-1 as a New Macromolecular Drug Target in the Prevention of Inflammation and Cancer
Anti-Cancer Agents in Medicinal Chemistry Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets Statins and Solid Organ Transplantation
Current Pharmaceutical Design NBS1 Heterozygosity and Cancer Risk
Current Genomics How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation
Current Drug Metabolism Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry